however, the clinical significance and durability of these effects remain under investigation
Formulated without Parabens, Sulfates or Phthalates
Dose increases within the range determined by the prescribing physician may be considered for patients who are tolerating the medication well, based on provider assessment
In the SURPASS clinical trial program for type 2 diabetes (Mounjaro), constipation was reported in approximately 12-17% of patients across the 5 mg, 10 mg, and 15 mg weekly doses, with higher rates generally observed at higher doses
However, efficacy remains proven predominantly only in vitro or in animals
Our leaders, researchers and innovators collaborate with specialists and care team members to create treatment plans for optimal clinical outcomes